Immunotherapy has become the central pillar of cancer therapy. Immune checkpoint
inhibitors (ICIs), a major category of tumor immunotherapy, reactivate preexisting anticancer …

Adjuvant and neoadjuvant therapies that reduce the risk of renal cell carcinoma (RCC)
recurrence remain an area of unmet need. Advances have been made in metastatic RCC …

Abstract In KEYNOTE-564, adjuvant pembrolizumab, a PD-1 antibody, significantly
improved disease-free survival (DFS) in localised clear-cell renal cell carcinoma (ccRCC) …

Perioperative immune checkpoint inhibitor (ICI) trials for intermediate high-risk clear cell
renal cell carcinoma (ccRCC) have failed to consistently demonstrate improved patient …

Standard treatment for localized non-metastatic renal cell carcinoma (RCC) is radical or
partial nephrectomy. However, after radical surgery, patients with stage II-III have a …

Purpose To analyze and summarize the efficacy of immune checkpoint inhibitor (ICI) alone
or in combination therapy for renal cell carcinoma (RCC) and urothelial carcinoma (UC) …

There have been significant advances in the treatment of urology cancers, with a number of
practice‐changing treatments. There is now greater clarity on the role of the use of …

Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current
standard of treatment in localized RCC is partial or complete nephrectomy. However, after …

Localized renal cell carcinoma (RCC) is primarily managed with nephrectomy, which is
performed with curative intent. However, disease recurs in~ 20% of patients. Treatment with …

Renal cell carcinoma (RCC) accounts for 2–3% of all malignant disease in adults, with 30%
of RCC diagnosed at locally advanced or metastatic stages of disease. A form of locally …